Kymera Therapeutics, Inc. $KYMR is AJU IB Investment Co. Ltd.’s 2nd Largest Position

AJU IB Investment Co. Ltd. lowered its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 95.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,648 shares of the company’s stock after selling 437,411 shares during the quarter. Kymera Therapeutics comprises approximately 8.0% of AJU IB Investment Co. Ltd.’s portfolio, making the stock its 2nd biggest position. AJU IB Investment Co. Ltd.’s holdings in Kymera Therapeutics were worth $1,529,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after acquiring an additional 815 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Kymera Therapeutics during the second quarter valued at approximately $73,000. Finally, US Bancorp DE increased its position in shares of Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after acquiring an additional 166 shares in the last quarter.

Insiders Place Their Bets

In other Kymera Therapeutics news, insider Noah Goodman sold 1,347 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $90.00, for a total value of $121,230.00. Following the completion of the sale, the insider owned 50,195 shares of the company’s stock, valued at approximately $4,517,550. The trade was a 2.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce Booth sold 5,900 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the sale, the director directly owned 5,641 shares of the company’s stock, valued at approximately $507,464.36. This trade represents a 51.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 370,918 shares of company stock worth $31,120,324 in the last 90 days. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Trading Down 0.3%

NASDAQ:KYMR opened at $81.46 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $28.50 and a 12 month high of $103.00. The company has a market cap of $6.70 billion, a PE ratio of -22.82 and a beta of 2.06. The company has a 50 day simple moving average of $83.29 and a two-hundred day simple moving average of $79.30.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the previous year, the firm posted ($0.82) EPS. The firm’s revenue was up 55.5% on a year-over-year basis. Research analysts forecast that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KYMR shares. UBS Group raised their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. BTIG Research reduced their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Citigroup lifted their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.